Authors

Sapna Patel, MD, is a professor in the Division of Medical Oncology, the leader of the Cutaneous Oncology Program, and the William Robinson Endowed Chair in Cancer Research at the University of Colorado Cancer Center.

Latest:

An Introduction to T-cell Receptor T-cell (TCR-T) Therapy

Panelists discuss the distinctions among tumor-infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) T-cell, and T-cell receptor T-cell (TCR-T) therapies in melanoma, emphasizing TIL therapy’s polyclonal nature and regulatory challenges while highlighting the promise of engineered TCR-T cells and the need to balance scientific validation with clinical feasibility to maintain access to innovative treatments.

Jathin Bandari, MD

Latest:

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Hadeel Assad, MD

Hadeel Assad, MD, is an associate professor, clinician educator, and medical oncologist at Wayne State University and Karmanos Cancer Institute

Latest:

The Move From Blood to Solid: Open Opportunities for CAR T-Cell Therapy in Solid Tumors

There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.

Fortunato Ciardiello, MD, PhD, University of Campania

Latest:

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC

Josh Ruess, MD 

Latest:

Optimizing Adjuvant Therapy Decisions in Resectable NSCLC: Integrating Pathologic Response, PD-L1, and Nodal Status

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

Tisch Cancer Institute

Latest:

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Eric A. Singer, MD

Latest:

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Pancreatic Cancer Spreads to Liver or Lung Thanks to This Protein

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Jin-Ji Yang, MD

Jin-Ji Yang, MD is an oncologist at Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, at the Guangdong Academy of Medical Sciences at the Southern Medical University.

Latest:

Dr Yang on Osimertinib Plus Savolitinib in MET-Aberrant, EGFR-Mutant Advanced NSCLC

Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Phulong L. Mai, MD

Latest:

Dr. Mai on Barriers of Genetic Testing in CRC

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Meriem Mokhtech, MD

Latest:

Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

John Crown, BCh, BAO, BSc, MD, MBA

Latest:

Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Susan E. Waltz, PhD

Latest:

Women in Oncology: Self-Advocacy in a Busy Field

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.

Janet Abrahm, MD, FACP, FAAHPM

Latest:

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

Roisin E. O'Cearbhaill, MD

Latest:

Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.

Alexandre A. Jácome, MD, PhD

Latest:

Test for Summarization

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

Milana Dolezal, MD, MSci

Latest:

Patient Profile 2: 3L Therapy for Triple-Positive mBC

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Anita D’Souza, MD

Latest:

Dr. D’Souza on the Utilization of Monoclonal Antibodies and Immunomodulating Agents in AL Amyloidosis

Anita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.

Danielle Krause, MD

Latest:

Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Amgen Sponsored Content; OncLive Article with Dr. Edward S. Kim

Latest:

Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment Journey

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.